Enfortumab vedotin versus platinum rechallenge in post‐platinum, post‐pembrolizumab advanced urothelial carcinoma: A multicenter propensity score‐matched study.
Saved in:
| Title: | Enfortumab vedotin versus platinum rechallenge in post‐platinum, post‐pembrolizumab advanced urothelial carcinoma: A multicenter propensity score‐matched study. |
|---|---|
| Authors: | Taguchi, Satoru1 (AUTHOR), Kawai, Taketo1,2 (AUTHOR) taketokawai@yahoo.co.jp, Ambe, Yoshiki1 (AUTHOR), Kishitani, Kenjiro1 (AUTHOR), Sugimoto, Kazuma3 (AUTHOR), Miyakawa, Jimpei3 (AUTHOR), Nakamura, Yu3 (AUTHOR), Noda, Michio2 (AUTHOR), Kaneko, Tomoyuki2 (AUTHOR), Kamei, Jun1,4 (AUTHOR), Obinata, Daisuke5 (AUTHOR), Yamaguchi, Kenya5 (AUTHOR), Kakutani, Shigenori6 (AUTHOR), Furuya, Yoshitsune7 (AUTHOR), Sato, Yujiro7 (AUTHOR), Uemura, Yukari8 (AUTHOR), Akiyama, Yoshiyuki1 (AUTHOR), Yamada, Yuta1 (AUTHOR), Sato, Yusuke1 (AUTHOR), Yamada, Daisuke1 (AUTHOR) |
| Source: | International Journal of Urology. Dec2023, Vol. 30 Issue 12, p1180-1186. 7p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
